Toll Free: 1-888-928-9744

Wounds - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 224 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Wounds - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H2 2016, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 56, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Wounds Overview 10 Therapeutics Development 11 Pipeline Products for Wounds - Overview 11 Pipeline Products for Wounds - Comparative Analysis 12 Wounds - Therapeutics under Development by Companies 13 Wounds - Therapeutics under Investigation by Universities/Institutes 17 Wounds - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Wounds - Products under Development by Companies 23 Wounds - Products under Investigation by Universities/Institutes 28 Wounds - Companies Involved in Therapeutics Development 30 Aerpio Therapeutics Inc 30 AlgiPharma AS 31 AmpliPhi Biosciences Corp 32 AndroScience Corp 33 Aridis Pharmaceuticals LLC 34 Beech Tree Labs Inc 35 Bio3 Research Srl 36 Biotec Pharmacon ASA 37 Blueberry Therapeutics Ltd 38 Cellphire Inc 39 CorMedix Inc 40 Dermala Inc 41 Destiny Pharma Ltd 42 Escape Therapeutics Inc 43 EyeGene Inc 44 FibroGen Inc 45 GangaGen Inc 46 Gene Signal International SA 47 GlaxoSmithKline Plc 48 IC-MedTech Inc 49 Living Cell Technologies Ltd 50 Madam Therapeutics BV 51 miRagen Therapeutics Inc 52 NatureWise Biotech & Medicals Corp 53 Novan Inc 54 NuvOx Pharma LLC 55 Octapharma AG 56 Omeros Corp 57 Osiris Therapeutics Inc 58 Pacific Northwest Biotechnology LLC 59 Pharmaxis Ltd 60 ProMetic Life Sciences Inc 61 RiverTown Therapeutics Inc 62 RMB-Research GmbH 63 RXi Pharmaceuticals Corp 64 Sinclair Pharma Plc 65 SomaGenics Inc 66 Stratatech Corp 67 TGV-Laboratories 68 Thesan Pharmaceuticals Inc 69 Topadur Pharma AG 70 Trophogen Inc 71 Tumorend LLC 72 VBS Pharmaceuticals 73 viDA Therapeutics Inc 74 Wounds - Therapeutics Assessment 75 Assessment by Monotherapy Products 75 Assessment by Combination Products 76 Assessment by Target 77 Assessment by Mechanism of Action 80 Assessment by Route of Administration 83 Assessment by Molecule Type 85 Drug Profiles 87 (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 87 A-3APO - Drug Profile 88 ABSA-01 - Drug Profile 89 AKB-4924 - Drug Profile 92 ALLO-ASC - Drug Profile 93 AlloGraf - Drug Profile 94 Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 95 APO-1 - Drug Profile 96 APO-2 - Drug Profile 97 AR-101 - Drug Profile 98 Arginine Butyrate - Drug Profile 99 ARN-077 - Drug Profile 100 ASCJ-9 - Drug Profile 101 B-244 - Drug Profile 103 BB-1000 - Drug Profile 104 BDM-I - Drug Profile 105 BTL-slo - Drug Profile 107 CAR Peptide - Drug Profile 108 Cell Therapy for Chronic Wounds - Drug Profile 109 Cell Therapy for Dermatology and Immunology - Drug Profile 110 Cell Therapy for Wounds - Drug Profile 112 CM-101 - Drug Profile 113 CRMD-004 - Drug Profile 114 CTR-2 - Drug Profile 115 daprodustat - Drug Profile 116 DB-2121 - Drug Profile 119 Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 120 Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 121 Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 122 EGS-001 - Drug Profile 123 FG-6874 - Drug Profile 124 G-3KL - Drug Profile 125 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 126 Gene Therapy to Activate HSP60 for Wounds - Drug Profile 127 GS-156 - Drug Profile 128 Human Growth Factor - Drug Profile 129 hVGF - Drug Profile 130 JM-2 - Drug Profile 131 KL-7016 - Drug Profile 132 LWnt-3a - Drug Profile 133 MG-53 - Drug Profile 134 MMP-26051 - Drug Profile 136 MMP-26052 - Drug Profile 137 molgramostim - Drug Profile 138 Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 139 MRG-110 - Drug Profile 140 Mul-1867 - Drug Profile 141 NBM-67 - Drug Profile 142 ND-336 - Drug Profile 143 NTCELL - Drug Profile 144 Oligomer G for Wounds And Burns - Drug Profile 148 OTI-1011 - Drug Profile 149 OTI-1502 - Drug Profile 150 P-128 - Drug Profile 151 P-148 - Drug Profile 152 Panaecin - Drug Profile 153 perflenapent for wound healing - Drug Profile 154 Perlecan - Drug Profile 155 PGF - Drug Profile 157 plasminogen (recombinant) - Drug Profile 158 Polysaccharide for Wounds and Scars - Drug Profile 159 Protein for Diabetic Wound Healing - Drug Profile 160 Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 161 Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 162 Protein to Activate FGF2 for Wound Healing - Drug Profile 163 Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 164 PXS-4820 - Drug Profile 165 Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 166 Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 167 Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 168 Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile 169 Recombinant Protein to Inhibit SEB and TSST-1 for Pulmonary Infections, Bacterial Infections, Toxic Shock and Wounds - Drug Profile 170 Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 171 RT-1740 - Drug Profile 172 SG-404 - Drug Profile 173 silver sulfadiazine - Drug Profile 174 Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 175 Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 176 Small Molecule to Target LGR6 for Dermatology - Drug Profile 177 Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 178 Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 179 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 180 Soluble Beta Glucan - Drug Profile 181 Statmicoll - Drug Profile 184 Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 185 Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 186 Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 187 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 188 Thrombosomes - Drug Profile 190 Tolecine - Drug Profile 191 TOPN-53 - Drug Profile 192 TRBN-0224 - Drug Profile 193 TWB-103 - Drug Profile 195 V-2248 - Drug Profile 196 VTI-3000 Series - Drug Profile 197 WH-1 - Drug Profile 198 XF-70 - Drug Profile 199 Wounds - Dormant Projects 200 Wounds - Discontinued Products 209 Wounds - Product Development Milestones 210 Featured News & Press Releases 210 Appendix 216 Methodology 216 Coverage 216 Secondary Research 216 Primary Research 216 Expert Panel Validation 216 Contact Us 216 Disclaimer 217
List of Tables
Number of Products under Development for Wounds, H2 2016 18 Number of Products under Development for Wounds - Comparative Analysis, H2 2016 19 Number of Products under Development by Companies, H2 2016 20 Number of Products under Development by Companies, H2 2016 (Contd..1) 21 Number of Products under Development by Companies, H2 2016 (Contd..2) 22 Number of Products under Development by Companies, H2 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2016 25 Comparative Analysis by Late Stage Development, H2 2016 26 Comparative Analysis by Clinical Stage Development, H2 2016 27 Comparative Analysis by Early Stage Development, H2 2016 28 Comparative Analysis by Unknown Stage Development, H2 2016 29 Products under Development by Companies, H2 2016 30 Products under Development by Companies, H2 2016 (Contd..1) 31 Products under Development by Companies, H2 2016 (Contd..2) 32 Products under Development by Companies, H2 2016 (Contd..3) 33 Products under Development by Companies, H2 2016 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2016 35 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36 Wounds - Pipeline by Aerpio Therapeutics Inc, H2 2016 37 Wounds - Pipeline by AlgiPharma AS, H2 2016 38 Wounds - Pipeline by AmpliPhi Biosciences Corp, H2 2016 39 Wounds - Pipeline by AndroScience Corp, H2 2016 40 Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 41 Wounds - Pipeline by Beech Tree Labs Inc, H2 2016 42 Wounds - Pipeline by Bio3 Research Srl, H2 2016 43 Wounds - Pipeline by Biotec Pharmacon ASA, H2 2016 44 Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2016 45 Wounds - Pipeline by Cellphire Inc, H2 2016 46 Wounds - Pipeline by CorMedix Inc, H2 2016 47 Wounds - Pipeline by Dermala Inc, H2 2016 48 Wounds - Pipeline by Destiny Pharma Ltd, H2 2016 49 Wounds - Pipeline by Escape Therapeutics Inc, H2 2016 50 Wounds - Pipeline by EyeGene Inc, H2 2016 51 Wounds - Pipeline by FibroGen Inc, H2 2016 52 Wounds - Pipeline by GangaGen Inc, H2 2016 53 Wounds - Pipeline by Gene Signal International SA, H2 2016 54 Wounds - Pipeline by GlaxoSmithKline Plc, H2 2016 55 Wounds - Pipeline by IC-MedTech Inc, H2 2016 56 Wounds - Pipeline by Living Cell Technologies Ltd, H2 2016 57 Wounds - Pipeline by Madam Therapeutics BV, H2 2016 58 Wounds - Pipeline by miRagen Therapeutics Inc, H2 2016 59 Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H2 2016 60 Wounds - Pipeline by Novan Inc, H2 2016 61 Wounds - Pipeline by NuvOx Pharma LLC, H2 2016 62 Wounds - Pipeline by Octapharma AG, H2 2016 63 Wounds - Pipeline by Omeros Corp, H2 2016 64 Wounds - Pipeline by Osiris Therapeutics Inc, H2 2016 65 Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H2 2016 66 Wounds - Pipeline by Pharmaxis Ltd, H2 2016 67 Wounds - Pipeline by ProMetic Life Sciences Inc, H2 2016 68 Wounds - Pipeline by RiverTown Therapeutics Inc, H2 2016 69 Wounds - Pipeline by RMB-Research GmbH, H2 2016 70 Wounds - Pipeline by RXi Pharmaceuticals Corp, H2 2016 71 Wounds - Pipeline by Sinclair Pharma Plc, H2 2016 72 Wounds - Pipeline by SomaGenics Inc, H2 2016 73 Wounds - Pipeline by Stratatech Corp, H2 2016 74 Wounds - Pipeline by TGV-Laboratories, H2 2016 75 Wounds - Pipeline by Thesan Pharmaceuticals Inc, H2 2016 76 Wounds - Pipeline by Topadur Pharma AG, H2 2016 77 Wounds - Pipeline by Trophogen Inc, H2 2016 78 Wounds - Pipeline by Tumorend LLC, H2 2016 79 Wounds - Pipeline by VBS Pharmaceuticals, H2 2016 80 Wounds - Pipeline by viDA Therapeutics Inc, H2 2016 81 Assessment by Monotherapy Products, H2 2016 82 Assessment by Combination Products, H2 2016 83 Number of Products by Stage and Target, H2 2016 85 Number of Products by Stage and Mechanism of Action, H2 2016 88 Number of Products by Stage and Route of Administration, H2 2016 91 Number of Products by Stage and Molecule Type, H2 2016 93 Wounds - Dormant Projects, H2 2016 207 Wounds - Dormant Projects (Contd..1), H2 2016 208 Wounds - Dormant Projects (Contd..2), H2 2016 209 Wounds - Dormant Projects (Contd..3), H2 2016 210 Wounds - Dormant Projects (Contd..4), H2 2016 211 Wounds - Dormant Projects (Contd..5), H2 2016 212 Wounds - Dormant Projects (Contd..6), H2 2016 213 Wounds - Dormant Projects (Contd..7), H2 2016 214 Wounds - Dormant Projects (Contd..8), H2 2016 215 Wounds - Discontinued Products, H2 2016 216



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify